| |
|
|
|
Xtalks, online
2023 -7-20
With billions of neurons, the brain is the most complex organ in the body, so it’s not surprising that neuroscience trials — more so than clinical trials in other medical specialties — face major challenges. Despite the volume of research and funding, neuroscience clinical trials continue to fail for many reasons. Among them are the lack of reliable biomarkers, subjective outcome parameters and high placebo response rates.
For developers of neuroscience therapies, appropriately leveraging risk detection early during a clinical trial can significantly increase the ability to intervene and apply remediation timely, thereby improving the probability of success for the clinical study.
Join this webinar to explore the key factors contributing to the failure of neuroscience trials and learn effective risk detection strategies to enhance success rates.
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Dr. Andreas Schreiner, MD, Senior Vice President, Medical Affairs, Neuroscience and Analgesia, Premier Research Adam Simmons, Executive Director, Program Strategy, Neuroscience, Premier Research
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2023 -7-20
|
|
|
|
|
|
|
|
Registration:
|
|
Free registration
|
|
|
E-mail:
|
|
ajuurinen@xtalks.com
|
|
|
|
|
|
|
|
|